This luxury capitulation has barely begun
Investors greeted LVMH’s disappointing sales with surprising aplomb
The business of luxury is seduction. The aesthetics, the textures, the aura of exclusivity all conspire to turn savvy customers into true believers. That logic is not supposed to apply to hard-nosed investors. Yet their approach to the sector also veers into blind faith.
See, for instance, the market’s reaction to LVMH’s — horrible — sales. The luxury juggernaut’s key fashion and leather goods business, which includes brands such as LV and Dior, was down 5 per cent in the third quarter as the Chinese consumer finally capitulated. That points to a much sharper slowdown than feared.
Yet investors greeted this with surprising aplomb. Indeed, the main shock over Wednesday’s mini luxury sell-off was just how mini it was. Competitors were down a couple of percentage points. And LVMH itself fell less than the magnitude of cuts to forecast earnings. Indeed, at 21 times next year’s earnings, the group’s valuation is not far off from mid-cycle multiples of 23 to 24 times, according to Thomas Chauvet at Citigroup. The market, it seems, sees this as a classic macro downturn — and one that will soon reverse.
That is rich. It assumes that China’s as-yet-hazy stimulus programme will rapidly feed through into higher consumption. Analysts, for instance, are pencilling in mid-single-digit sales growth for LVMH next year.
More worryingly, it is by no means clear that, when the macro drag eventually clears, the luxury sector will seamlessly return to rapid growth. Successive price rises may have turned some customers off. In an era of fantastically chic but not terribly exciting “quiet luxury”, there are also murmurs about product desirability.
That leaves the luxury sector as a whole exposed to further disappointments. True super-premium companies such as Hermès and Ferrari — impervious both to macro and fashion cycles — should be relatively sheltered. Brands such as Prada/Miu Miu, which have recently found favour with consumers, might be cushioned from the worst of the impact.
LVMH is not in this camp. The group’s heft has traditionally been an advantage, enabling it to invest in talent, marketing and real estate. But momentum at LV and Dior has been relatively weak, suggests a Bernstein analysis of brand desirability. It may not help that the group is in the midst of a creative and managerial transition, which will take time to gain traction.
LVMH’s premium to the sector has compressed from about 40 per cent in March to about 6 per cent today, on Bloomberg numbers. The luxury sector is a long way from regaining its swagger. And LVMH, unusually, has work to do itself to recover its shine.
Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PENG -13.5%, EPAC -6.8% (also names new CFO), IBKR -3.9%, OMC -3.6%, ASML -3.1%, SVCO -2.4%, VSEC -1.1% (also to acquire Kellstrom Aerospace for ~ $200 mln; also prices offering of 1,724,137 shares of its common stock at $87.00 per share), CFG -1.1%, HWC -1%, FULT -1%
Other news:
- NBR -4.1% (disclosed additional merger details)
- INTC -1.8% (QCOM to wait until after US election before deciding on offer to buy INTC, according to Bloomberg)
- AEHR -1.5% (files $100 mln mixed shelf securities offering)
- LBRT -1.3% (increases dividend)
- APGE -1.3% (Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting)
- CSTL -1.3% (announces the publication of two recent studies that provide further support for the clinical need of its MyPath Melanoma gene expression profile test)
- GIB -1.2% (signed an agreement with the Swedish Tax Agency to deliver e-identification and electronic signature services)
- BZ -1.1% (disclosed voluntary announcement purchase of 144,356 shares on market pursuant to post-IPO share scheme)
Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- JBHT +7.3%, SYF +5.3%, MS +2.7%, OFG +2.6%, PNFP +2.4%, USB +1.7%, UAL +1.4% (also authorizes new $1.5 bln share and warrant repurchase program), EQBK +1.3%, FHN +0.8%
Other news:
- TCS +34.2% (BYON and TCS announce partnership; BYON to invest $40 mln in TCS)
- NVCR +22.2% (FDA approves Novocure's Optune Lua)
- LAC +19.9% (General Motors (GM) to contribute combined $625 million in cash and letters of credit to new joint venture with Lithium Americas)
- AMPS +16.6% (formal review of strategic alternatives has been underway)
- ANGI +3.6% (names new COO)
- ELAN +2.9% (presented the abstract titled "Serologic response to core booster vaccinations in dogs treated with a novel JAK inhibitor" at the International Society for Companion Animal Infectious Diseases (ISCAID) symposium)
- ACET +2.9% (FDA has agreed to an amendment to the Company's Investigational New Drug application to evaluate ADI-001)
- SGMT +2.5% (Announces Upcoming Presentations at AASLD - The Liver Meeting 2024)
- EXAI +2.2% (announces the advancement of two additional discovery programs within its collaboration with Sanofi (SNY), with Exscientia receiving an aggregate of $15 mln in milestone payments)
- SHIP +2% (George Economou / Sphinx Investment affirmed 9% active stake; filed motion for preliminary injunction)
- CPA +1.6% (reports September traffic)
- SERV +1.6% (unveils third-generation autonomous delivery robot, which has entered manufacturing with 2,000 new units on track to be deployed in 2025 on Uber Eats platform)
- BYON +1.5% (BYON and TCS announce partnership; BYON to invest $40 mln in TCS)
- WDS +1.3% (reports Q3 production)
- GWRE +1.2% (prices offering of $600.0 mln of 1.25% convertible senior notes due 2029)
- ENLC +1.2% (confirmed changes to Board of Directors to reflect new ONEOK (OKE) controlling interest)
- PLCE +1.1% (files for subscription rights to purchase up to $90 mln in stock)
- WVE +1.1% (was notified that Takeda (TAK) did not intend to exercise and therefore elected to terminate its option for the Huntingtin target Collaboration and License Agreement)
- UNFI +1% (releases Grocery Wholesale Distribution Business presentation; provides 3-Year Financial Objectives)
- CGEM +1% (FDA cleared the Company's Investigational New Drug Application for CLN-978 and its global Phase 1 clinical trial may proceed in the U.S. to assess CLN-978)
Research Calls I
-
Upgrades:
- AptarGroup (ATR) upgraded to Buy from Hold at DBS Bank
- Cisco (CSCO) upgraded to Buy from Neutral at Citigroup; tgt raised to $62
- Cognex (CGNX) upgraded to Overweight from Equal-Weight at Stephens; tgt raised to $55
- Corteva (CTVA) upgraded to Buy from Neutral at BofA Securities; tgt raised to $67
- Grainger (GWW) upgraded to Outperform from Neutral at Robert W. Baird; tgt raised to $1230
- NovoCure (NVCR) upgraded to Buy from Neutral at H.C. Wainwright; tgt raised to $30
- Universal Health (UHS) upgraded to Buy from Hold at TD Cowen; tgt raised to $283
- Wesco (WCC) upgraded to Outperform from Neutral at Robert W. Baird; tgt raised to $550
- Westlake Corporation (WLK) upgraded to Neutral from Underperform at BofA Securities; tgt raised to $159
-
Downgrades:
- Carrier Global (CARR) downgraded to Equal-Weight from Overweight at Stephens; tgt raised to $85
- CF Industries (CF) downgraded to Underperform from Neutral at BofA Securities; tgt $83
- Eastman Chemical (EMN) downgraded to Neutral from Buy at BofA Securities; tgt raised to $119
- Emerson (EMR) downgraded to Equal-Weight from Overweight at Stephens; tgt lowered to $120
- Enphase Energy (ENPH) downgraded to Neutral from Positive at Susquehanna; tgt lowered to $104
- Estee Lauder (EL) downgraded to Hold from Buy at HSBC Securities; tgt $100
- L'Oreal (LRLCY) downgraded to Underweight from Neutral at JP Morgan
- Omnicom (OMC) downgraded to Equal Weight from Overweight at Wells Fargo; tgt raised to $110
- Piedmont Lithium (PLL) downgraded to Underperform from Neutral at Macquarie; tgt $7.80
- Sitio Royalties Corp. (STR) downgraded to Sector Weight from Overweight at KeyBanc Capital Markets
- Yum! Brands (YUM) downgraded to Hold from Buy at TD Cowen; tgt lowered to $145
-
Others:
- Advance Auto (AAP) resumed with a Neutral at ROTH MKM; tgt $40
- Antero Resources (AR) initiated with a Neutral at UBS; tgt $33
- Apellis Pharmaceuticals (APLS) initiated with an Outperform at William Blair
- Asure Software (ASUR) initiated with an Overweight at Stephens; tgt $13
- Autodesk (ADSK) initiated with an Overweight at Wells Fargo; tgt $340
- Benitec Biopharma (BNTC) initiated with an Outperform at Oppenheimer; tgt $35
- Brookdale Senior Living (BKD) initiated with a Buy at Jefferies; tgt $8
- Burke & Herbert Financial Services Corp. (BHRB) initiated with a Buy at DA Davidson; tgt $76
- California Resources Corp (CRC) initiated with a Buy at UBS; tgt $68
- Chord Energy (CHRD) initiated with a Buy at UBS; tgt $168
- Civitas Resources (CIVI) initiated with a Neutral at UBS; tgt $60
- Freshworks (FRSH) initiated with an Equal Weight at Wells Fargo; tgt $11
- Instacart (CART) initiated with a Hold at Jefferies; tgt $43
- Klaviyo (KVYO) initiated with an Equal Weight at Wells Fargo; tgt $37
- Larimar Therapeutics (LRMR) initiated with an Outperform at Oppenheimer; tgt $26
- O'Reilly Auto (ORLY) resumed with a Buy at ROTH MKM; tgt $1337
- Paycor (PYCR) initiated with an Overweight at Stephens; tgt $18
- Qualcomm (QCOM) added to 30-day negative catalyst watch at Citigroup
- Qualys (QLYS) initiated with a Hold at Jefferies; tgt $135
- Rapid7 (RPD) initiated with a Buy at Jefferies; tgt $50
- RLI Corp (RLI) initiated with a Perform at Oppenheimer
- Tenable (TENB) initiated with a Hold at Jefferies; tgt $45
- Veracyte (VCYT) initiated with a Buy at UBS; tgt $43
- Voyager Therapeutics (VYGR) initiated with an Outperform at Leerink Partners; tgt $15
- Walt Disney (DIS) initiated with a Neutral at Piper Sandler; tgt $95